TuHURA Biosciences Inc美股招股说明书(2026-04-08版)

$50,000,000 Common Stock We have entered into an At the Market Offering Agreement (the “Sales Agreement”), dated November3, 2025, with H.C. Wainwright& Co., LLC(the “Sales Agent”), relating to the shares of our common stock, par value $0.001 per share (the “Common Stock”), offered by this prospectussupplement. In accordance with the terms of the Sales Agreement, we may offer and sell shares of our Common Stock having an aggregate offeringprice of up to $50,000,000 from time to time through or to the Sales Agent, as agent and/or principal. Sales of Common Stock, if any, under this prospectus supplement and the accompanying prospectus may be made in transactions that are deemedto be “at-the-market offerings” as defined in Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”), including sales made directlyon or through the Nasdaq Capital Market, or any other existing trading market in the United States for our common stock, sales made to or through amarket maker other than on an exchange or otherwise, directly to the Sales Agent as principal, in negotiated transactions at market prices prevailing atthe time of sale or at prices related to such prevailing market prices and/or in any other method permitted by law. If we and the Sales Agent agree on anymethod of distribution other than sales of our common stock into The Nasdaq Capital Market or another existing trading market in the United States atmarket prices, we will file a further prospectus supplement providing all information about such offering as required by Rule 424(b) under the SecuritiesAct. The Sales Agent is not required to sell any specific number or dollar amount of shares, but will act as sales agent on a commercially reasonableefforts basis. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. The Sales Agent will be entitled to compensation under the terms of the Sales Agreement at a commission rate of 3.0% of the gross sales price pershare of Common Stock issued by us and sold through them as our Sales Agent. In connection with the sale of Common Stock on our behalf, the SalesAgent will be deemed to be an “underwriter” within the meaning of the Securities Act and the compensation to the Sales Agent will be deemed to beunderwriting commissions or discounts. We have also agreed to provide indemnification and contribution to the Sales Agent with respect to certainliabilities, including liabilities under the Securities Act. Our Common Stock is traded on the Nasdaq Capital Market under the symbol “HURA.” On March31, 2026, the last reported sales price of ourCommon Stock was $1.79 per share. Investment in our Common Stock involves risks. See the section entitled “RiskFactors” on page S-6 of thisprospectus supplement and the risk factors contained in the documents incorporated by reference in this prospectussupplement and the accompanying prospectus for a discussion of certain factors which should be considered beforeinvesting in our Common Stock. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities ordetermined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. H.C. Wainwright& Co. Table of Contents TABLE OF CONTENTS ABOUT THIS PROSPECTUS SUPPLEMENTCAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSPROSPECTUS SUPPLEMENT SUMMARYTHE OFFERINGRISK FACTORSUSE OF PROCEEDSDILUTIONPLAN OF DISTRIBUTIONLEGAL MATTERSEXPERTSWHERE YOU CAN FIND MORE INFORMATION SELLING STOCKHOLDERS WHERE YOU CAN FIND MORE INFORMATION We are responsible for the information contained and incorporated by reference in this prospectus supplement and the accompanying prospectus.We have not authorized anyone to give you any other information, and we take no responsibility for any other information that others may give you. Ifyou are in a jurisdiction where offers to sell, or solicitations of offers to purchase, the securities offered by this documentation are unlawful, or if you area person to whom it is unlawful to direct these types of activities, then the offer presented in this document does not extend to you. The informationcontained in this document speaks only as of the date of this document, unless the information specifically indicates that another date applies. Ourbusiness, financial condition, results of operations and prospects may have changed since those dates. Table of Contents ABOUT THIS PROSPECTUS SUPPLEMENT This prospectus supplement and the accompanying prospectus are part of a “shelf” registration statement on Form S-3 that we filed with theSecurities and Exchange Commission (the “SEC”) on November3, 2025. Under this “shelf” registration process, we may offer and sell any combinationof the securities described in the accompanying prospectus, from time to time, in one or more offerings, in an aggregate amount not to exceed$250,000,000. Under this prospectus sup